Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07444476 · ClinicalTrials.gov registry record · Phase 3

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam

A Phase 3 study, sponsored by Biogen.

Recruiting
Registry status
Phase 3
Development phase
90
Enrollment target

NCT07444476 is a Phase 3 study that is actively recruiting participants, run by Biogen. The registered enrollment target is 90 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07444476, a Phase 3 study, is actively recruiting participants, sponsored by Biogen.

RECRUITING
Registry status
Phase 3
Development phase
90 participants
Enrollment target

Study Summary

In this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in individuals with SMA who are between the ages of 15 and 60 years old. In most people living with SMA, changes to or a lack of a gene called survival motor neuron 1 (SMN1) - often referred to as gene mutations or variants - affect how this gene works. As a result, their bodies produce less SMN protein. Without enough of this protein, motor neurons and muscles cannot work properly. There is a similar gene called SMN2 that produces SMN protein, but it usually does not produce enough SMN protein on its own to make up for the changes in the SMN1 gene. Salanersen is a drug designed to help the SMN2 gene to make more working SMN protein. In this study, there will be 2 groups of participants: a group who has never received treatment for SMA before joining this study, and a group who has been treated with risdiplam, an approved drug for SMA . Those participants must not have received any other SMA treatments before and will need to stop their risdiplam treatment for the duration of the study. The main goal of this study is to learn more about how salanersen affects the participants' motor function. Researchers will use different tests and questionnaires to learn if motor function is changing over the study duration. The main question researchers want to answer in this study is: • For the group who has never been treated for SMA, how much do scores on the HFMSE movement test change at 12 months compared to the beginning of the study? The Hammersmith Functional Motor Scale - Expanded (HFMSE) has 33 activities that are scored which include sitting, lying down, walking, jumping, and more. Researchers will also learn more about: * The effects on participants' motor function and how well their nerves and muscles function. * The effects on participants' overall sense of change and how they perfor

Interventions

  • DRUG Salanersen

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2026-04-03
Est. Completion 2032-06-22
Phase Phase 3

Sponsor

Biogen

334 total trials

What the Registry Record Tells You About NCT07444476

The ClinicalTrials.gov registry entry for NCT07444476 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Salanersen is the first listed.

NCT07444476 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07444476 about?

NCT07444476 is a clinical study titled "A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam". In this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in individuals with SMA who are between the ages of 15 and 60 years old. In most people living with SMA, changes to or a...

What is the current status of trial NCT07444476?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2026-04-03. Estimated completion is 2032-06-22.

What interventions are being tested in trial NCT07444476?

The interventions under investigation include: Salanersen (DRUG).

Who is sponsoring clinical trial NCT07444476?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.